Clinical trials: Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation

Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

• Completed
• Age: 18 to 100 years
• Phase 1
• Results posted

To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.

Trial name

NCT04380753

Testing

AMG 510

Where

4 sites in Hong Kong, Taiwan

Volunteers

12 people

Sponsor

Amgen